Pfiz­er, Mer­ck KGaA hit the brakes on an­oth­er PhI­II as PD-L1 Baven­cio flops yet again

Pfiz­er and Mer­ck KGaA are ce­ment­ing in their dis­tant run­ner-up sta­tus for Baven­cio (avelum­ab), a PD-L1 check­point that just failed its fourth late-stage tri­al. And the drum­beat of set­backs — at a time check­points are pro­lif­er­at­ing around the world — will hurt their prospects for mak­ing this the block­buster they both need.

This time around re­searchers sim­ply said that Baven­cio in com­bi­na­tion with or fol­low­ing chemo in front­line ovar­i­an can­cer cas­es had failed the pri­ma­ry end­point on pro­gres­sion-free sur­vival, forc­ing them to draw a halt to the work.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER